OraVerse®
Phentolamine Mesylate

OraVerse® (Phentolamine Mesylate) accelerates the reversal of lingering soft tissue anesthesia associated with local anesthetic containing a vasoconstrictor.

Soft Tissue Anesthesia

When local anesthetics with vasoconstrictors are used for dental procedures, they produce prolonged loss of oral sensation and function.

Soft tissue anesthesia can lead to:

- Uncontrolled drooling
- Patient's perceived sense of altered appearance

Loss of function can lead to difficulty:

- Speaking
- Smiling
- Drinking

it's about time.

What is OraVerse?

OraVerse is a breakthrough that reverses unwanted lingering soft tissue anesthesia after routine dental procedures where a local anesthetic with a vasoconstrictor was used. In clinical trials, patients were able to regain lip sensation twice as fast as the control group.

OraVerse is indicated for the reversal of soft-tissue anesthesia, i.e., anesthesia of the lip and tongue, and the associated functional deficits resulting from an intraoral submucosal injection of a local anesthetic containing a vasoconstrictor.
Use in pediatric patients less than 3 years of age or <15 kg (33 lbs.) has not been established.

Important Safety Information

In clinical trials, the most common adverse events with OraVerse (phentolamine mesylate) vs. control were post procedural pain (6% vs. 6%), injection site pain (5% vs. 4%), tachycardia (5% vs. 6%), bradycardia (2% vs. 0.3%) and headache (3% vs. 4%). Following parenteral use of phentolamine in non-dental indications, myocardial infarction and cerebrovascular spasm and occlusion have been reported, usually in association with marked hypotensive episodes producing shock-like states. Although such effects are uncommon with OraVerse, clinicians should be alert to the signs and symptoms of tachycardia and cardiac arrhythmias, particularly in patients with a history of cardiovascular disease, as these symptoms may occur with the use of phentolamine or other alpha-adrenergic blocking agents.

Please see full prescribing information available from our representatives or on OraVerse.com.

OraVerse®
Phentolamine Mesylate

Safety Information

The safety of OraVerse® has been well demonstrated in multicenter, randomized, controlled clinical trials.

- In these trials, the adverse events of OraVerse were similar to the control group.
- The most common adverse event with OraVerse greater than the control group was injection site pain (5% vs. 4%).
- Refer to the Important Safety Information on the front panel for more information.

Patients can regain lip sensation faster.

In randomized, controlled, clinical trials, OraVerse patients were able to regain normal lip sensation twice as fast compared to the control group.

Contact your Septodont Rep for complimentary in office marketing materials (window cling, lobby sign, patient brochures) and also sign up to be on the OraVerse.com Doctor Locator for patients!

Median Time to Normal Lip Sensation



These studies showed that on average people who are given OraVerse not only return to normal sensation twice as fast, but they can smile, speak, and drink normally sooner, and drooling is minimized.

Median Time to Recovery of Normal Function



Distinguish your practice with OraVerse

OraVerse brings a new and innovative patient-centered service to your practice, restoring sensation and function after common restorative procedures like:

- Cavity preparations
- Crown preparations & placements
- Inlays, onlays & veneers
- Periodontal scaling and root planing

OraVerse is indicated for the reversal of soft-tissue anesthesia, i.e., anesthesia of the lip and tongue, and the associated functional deficits resulting from an intraoral submucosal injection of a local anesthetic containing a vasoconstrictor.

Use in pediatric patients less than 3 years of age or <15 kg (33 lbs.) has not been established.

See full prescribing information for more information.

septodont
205 Granite Run Drive
Suite 150
Lancaster, PA 17601
septodontusa.com

I.07.2016.US